Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors

JACOPO GIULIANI and ANDREA BONETTI
Anticancer Research July 2019, 39 (7) 3961-3965; DOI: https://doi.org/10.21873/anticanres.13550
JACOPO GIULIANI
Department of Oncology, Mater Salutis Hospital, Legnago, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jacopo.giuliani{at}aulss9.veneto.it
ANDREA BONETTI
Department of Oncology, Mater Salutis Hospital, Legnago, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 39 no. 7 3961-3965
DOI 
https://doi.org/10.21873/anticanres.13550
PMID 
31262928

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received March 31, 2019
  • Revision received May 25, 2019
  • Accepted May 28, 2019
  • Published online July 1, 2019.

Copyright & Usage 
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

Author Information

  1. JACOPO GIULIANI⇑ and
  2. ANDREA BONETTI
  1. Department of Oncology, Mater Salutis Hospital, Legnago, Italy
  1. Correspondence to: Jacopo Giuliani, Department of Oncology, Mater Salutis Hospital, Az. ULSS 9 Scaligera, Via Gianella 1, 37045 Legnago (VR), Italy. Tel: +39 0442622364, Fax: +39 0442622469, e-mail: jacopo.giuliani{at}aulss9.veneto.it
View Full Text

Statistics from Altmetric.com

Cited By...

  • 29 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 39, Issue 7
July 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
JACOPO GIULIANI, ANDREA BONETTI
Anticancer Research Jul 2019, 39 (7) 3961-3965; DOI: 10.21873/anticanres.13550

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Financial Toxicity and Non-small Cell Lung Cancer Treatment: The Optimization in the Choice of Immune Check Point Inhibitors
JACOPO GIULIANI, ANDREA BONETTI
Anticancer Research Jul 2019, 39 (7) 3961-3965; DOI: 10.21873/anticanres.13550
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
  • Financial toxicity in patients with lung cancer: a scoping review protocol
  • Inhibition of Cell-surface Molecular GPR87 With GPR87-suppressing Adenoviral Vector Disturb Tumor Proliferation in Lung Cancer Cells
  • Google Scholar

More in this TOC Section

  • Real-world Delivery and Outcomes of Intravesical BCG for Non–muscle-invasive Bladder Cancer
  • Early Progressive Disease Predicts Poor Outcomes of Second-line VEGFR Tyrosine Kinase Inhibitor Therapy After First-line Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma
  • Evaluation of Quality Metrics for Dose Assessment in Field Overlap Regions of VMAT-Based Craniospinal Axis Irradiation
Show more Clinical Studies

Keywords

  • NSCLC
  • first-line
  • second-line
  • phase III RCTs
  • pembrolizumab
  • nivolumab
  • atezolizumab
  • cost of drugs
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire